Research & Literature

Synovitis, acne, pustulosis, hyperostosis and osteitis syndrome: a single centre study of a cohort of 164 patients.

Li C, Zuo Y, Wu N, et al.

Rheumatology (Oxford, England) 2016; (55(6)):1023-30 doi:10.1093/rheumatology/kew015.

What do we know about palmoplantar pustulosis?

Misiak-Galazka M, Wolska H, Rudnicka L

Journal of the European Academy of Dermatology and Venereology : JEADV 2017; (31(1)):38-44 doi:10.1111/jdv.13846.

New Oral Therapies for Psoriasis: A Comprehensive Review.

Goldenberg G, Lanoue J, Dong J

The Journal of clinical and aesthetic dermatology 2016; (9(8)):25-8.

IgA pemphigus showing IgA antibodies to desmoglein 1 and 3.

Hegazy S, Bouchouicha S, Khaled A, et al.

Dermatology practical & conceptual 2016; (6(4)):31-33 doi:10.5826/dpc.0604a07.

Is palmoplantar pustulosis simply a variant of psoriasis or a distinct entity?

Misiak-Galazka M, Wolska H, Rudnicka L

Journal of the European Academy of Dermatology and Venereology : JEADV 2017; (31(7)):e342-e343 doi:10.1111/jdv.14136.

Bullous, pseudobullous, & pustular dermatoses.

Wick MR

Seminars in diagnostic pathology 2017; (34(3)):250-260 doi:10.1053/j.semdp.2016.12.001.

Retrospective analysis of the clinical response of palmoplantar pustulosis after dental infection control and dental metal removal.

Kouno M, Nishiyama A, Minabe M, et al.

The Journal of dermatology 2017; (44(6)):695-698 doi:10.1111/1346-8138.13751.

The P2X7 receptor is not essential for development of imiquimod-induced psoriasis-like inflammation in mice.

Geraghty NJ, Mansfield KJ, Fuller SJ, et al.

Purinergic signalling 2017; (13(4)):405-415 doi:10.1007/s11302-017-9569-0.

A case of bronchiolitis obliterans organising pneumonia associated with SAPHO (synovitis-acne-pustulosis-hyperostosis-osteitis) syndrome.

Hameed F, Steer H

BMJ case reports 2017; (2017()) doi:10.1136/bcr-2017-219822.

Clinical features and radiological findings of 67 patients with SAPHO syndrome.

Okuno H, Watanuki M, Kuwahara Y, et al.

Modern rheumatology 2018; (28(4)):703-708 doi:10.1080/14397595.2017.1372874.

Treatment outcome and prognostic factors of tonsillectomy for palmoplantar pustulosis and pustulotic arthro-osteitis: A retrospective subjective and objective quantitative analysis of 138 patients.

Takahara M, Hirata Y, Nagato T, et al.

The Journal of dermatology 2018; (45(7)):812-823 doi:10.1111/1346-8138.14348.

The microbiome of the "sterile" pustules in palmoplantar pustulosis.

Masuda-Kuroki K, Murakami M, Tokunaga N, et al.

Experimental dermatology 2018; (27(12)):1372-1377 doi:10.1111/exd.13791.

Palmoplantar pustulosis and IgA nephropathy.

Shimamura Y, Maeda T, Takizawa H

Journal of general and family medicine 2019; (20(1)):35-36 doi:10.1002/jgf2.218.

Clinical Characteristics of Japanese Patients with Palmoplantar Pustulosis.

Yamamoto T

Clinical drug investigation 2019; (39(3)):241-252 doi:10.1007/s40261-018-00745-6.

Efficacy of bisphosphonates in patients with synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome: a prospective open study.

Li C, Zhao Y, Zuo Y, et al.

Clinical and experimental rheumatology 2019; (37(4)):663-669.

Pompholyx vesicles contain small clusters of cells with high levels of hyaluronate resembling the pustulovesicles of palmoplantar pustulosis.

Murakami M, Muto J, Masuda-Kuroki K, et al.

The British journal of dermatology 2019; (181(6)):1325-1327 doi:10.1111/bjd.18261.

Efficacy and Safety of Guselkumab in Japanese Patients With Palmoplantar Pustulosis: A Phase 3 Randomized Clinical Trial.

Terui T, Kobayashi S, Okubo Y, et al.

JAMA dermatology 2019; (155(10)):1153-1161 doi:10.1001/jamadermatol.2019.1394.

Pathogenic role of palatine tonsils in palmoplantar pustulosis: A review.

Harabuchi Y, Takahara M

The Journal of dermatology 2019; (46(11)):931-939 doi:10.1111/1346-8138.15100.

How frequently does palmoplantar psoriasis affect the palms and/or soles? A systematic review and meta-analysis.

Timotijević ZS, Trajković G, Jankovic J, et al.

Postepy dermatologii i alergologii 2019; (36(5)):595-603 doi:10.5114/ada.2019.89508.

Characteristics of Japanese patients with pustulotic arthro-osteitis associated with palmoplantar pustulosis: a multicenter study.

Yamamoto T, Hiraiwa T, Tobita R, et al.

International journal of dermatology 2020; (59(4)):441-444 doi:10.1111/ijd.14788.

Palmoplantar pustulosis: Factors causing and influencing the course of the disease.

Putra-Szczepaniak M, Maj J, Jankowska-Konsur A, et al.

Advances in clinical and experimental medicine : official organ Wroclaw Medical University 2020; (29(1)):157-163 doi:10.17219/acem/112613.

Interleukin-17A and Keratinocytes in Psoriasis.

Furue M, Furue K, Tsuji G, Nakahara T

International journal of molecular sciences 2020; (21(4)) doi:10.3390/ijms21041275.

Paradoxical palmoplantar pustulosis induced by secukinumab and brodalumab: a report of three cases.

Mössner R, Pinter A

European journal of dermatology : EJD 2020; doi:10.1684/ejd.2020.3702.

Association of Clinical and Demographic Factors With the Severity of Palmoplantar Pustulosis.

Benzian-Olsson N, Dand N, Chaloner C, et al.

JAMA dermatology 2020; (156(11)):1216-1222 doi:10.1001/jamadermatol.2020.3275.

Interventions for chronic palmoplantar pustulosis: abridged Cochrane systematic review and GRADE assessments.

Obeid G, Do G, Kirby L, et al.

The British journal of dermatology 2021; (184(6)):1023-1032 doi:10.1111/bjd.19560.

Guselkumab improves joint pain in patients with pustulotic arthro-osteitis: A retrospective pilot study.

Ikumi N, Fujita H, Terui T

The Journal of dermatology 2021; (48(2)):199-202 doi:10.1111/1346-8138.15632.

Mandibular involvement in SAPHO syndrome: a retrospective study.

Wang M, Li Y, Cao Y, et al.

Orphanet journal of rare diseases 2020; (15(1)):312 doi:10.1186/s13023-020-01589-0.

Dabrafenib plus trametinib combination therapy triggered onset of pustulosis palmaris et plantaris in a patient with advanced cutaneous melanoma.

Muto Y, Fujimura T, Kambayashi Y, et al.

The Journal of dermatology 2021; (48(3)):e135-e136 doi:10.1111/1346-8138.15747.

Tonsillitis as a possible predisposition to synovitis, acne, pustulosis, hyperostosis and osteitis (SAPHO) syndrome.

Xiang Y, Wang Y, Cao Y, et al.

International journal of rheumatic diseases 2021; (24(4)):519-525 doi:10.1111/1756-185X.14064.

Pack-year cigarette smoking affects the course of palmoplantar pustulosis.

Putra-Szczepaniak M, Reich A, Jankowska-Konsur A, et al.

Advances in clinical and experimental medicine : official organ Wroclaw Medical University 2021; (30(2)):189-195 doi:10.17219/acem/131750.

Prevalence and incidence of palmoplantar pustulosis in Sweden: a population-based register study.

Löfvendahl S, Norlin JM, Schmitt-Egenolf M

The British journal of dermatology 2021; (185(5)):945-951 doi:10.1111/bjd.20087.

Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease.

Iznardo H, Puig L

International journal of molecular sciences 2021; (22(9)) doi:10.3390/ijms22094344.

Guselkumab for the Treatment of Palmoplantar Pustulosis: A Japanese Perspective.

Yamamoto T

Clinical pharmacology : advances and applications 2021; (13()):135-143 doi:10.2147/CPAA.S266223.

Clinical characteristics, quality of life and risk factors for severity in palmoplantar pustulosis: a cross-sectional, multicentre study of 263 patients.

Sarıkaya Solak S, Kara Polat A, Kilic S, et al.

Clinical and experimental dermatology 2022; (47(1)):63-71 doi:10.1111/ced.14829.

Anakinra for palmoplantar pustulosis: results from a randomized, double-blind, multicentre, two-staged, adaptive placebo-controlled trial (APRICOT).

Cro S, Cornelius VR, Pink AE, et al.

The British journal of dermatology 2021; doi:10.1111/bjd.20653.

Synovitis, Acne, Pustulosis, Hyperostosis, Osteitis (SAPHO) Syndrome: Clinical and Therapeutic Aspects.

Condé K, Guelngar CO, Mohamed A, et al.

Cureus 2021; (13(9)):e18332 doi:10.7759/cureus.18332.

Successful Treatment of Palmoplantar Pustulosis With Apremilast.

Dorgham N, Crasto D, Skopit S

Journal of drugs in dermatology : JDD 2021; (20(11)):1255-1256 doi:10.36849/jdd.6098.

The oral microbial composition and diversity affect the clinical course of palmoplantar pustulosis patients after dental focal infection treatment.

Akiyama Y, Minabe M, Inada J, et al.

Journal of dermatological science 2021; (104(3)):193-200 doi:10.1016/j.jdermsci.2021.11.001.

Pustular psoriasis as an autoinflammatory keratinization disease (AiKD): Genetic predisposing factors and promising therapeutic targets.

Akiyama M

Journal of dermatological science 2022; (105(1)):11-17 doi:10.1016/j.jdermsci.2021.11.009.

Papuloerythroderma of Ofuji associated with sternoclavicular arthritis and successful treatment with cyclosporine.

Kasai E, Habe K, Matsushima Y, et al.

JAAD case reports 2022; (27()):70-74 doi:10.1016/j.jdcr.2022.07.004.

Evaluation of the area subscore of the Palmoplantar Pustulosis Area and Severity Index using an attention U-net deep learning algorithm.

Paik K, Kim BR, Youn SW

The Journal of dermatology 2023; (50(6)):787-792 doi:10.1111/1346-8138.16752.

Non-bacterial vertebral osteitis as the first manifestation of pustulotic arthro-osteitis.

Ueda Y, Yokogawa N, Shimada K

Modern rheumatology case reports 2023; (7(2)):488-490 doi:10.1093/mrcr/rxad016.

An update on therapeutic options for palmoplantar pustulosis: a narrative review and expert recommendations.

Xu JM, Wang HM, Jin HZ

Expert review of clinical immunology 2023; (19(5)):499-516 doi:10.1080/1744666X.2023.2185775.

Spesolimab Efficacy and Safety in Patients with Moderate-to-Severe Palmoplantar Pustulosis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase IIb, Dose-Finding Study.

Burden AD, Bissonnette R, Navarini AA, et al.

Dermatology and therapy 2023; (13(10)):2279-2297 doi:10.1007/s13555-023-01002-1.

SAPHO syndrome: current clinical, diagnostic and treatment approaches.

Demirci Yildirim T, Sari İ

Rheumatology international 2024; (44(11)):2301-2313 doi:10.1007/s00296-023-05491-3.

Immunohistochemical evaluation of keratins and involucrin in differentiating between palmoplantar pustulosis and pompholyx.

Oh DY, Kim SJ, Jang YJ, et al.

International journal of dermatology 2024; (63(6)):780-786 doi:10.1111/ijd.17018.

Small-Molecule Inhibitors and Biologics for Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review and Network Meta-Analysis.

Huang IH, Wu PC, Chiu HY, Huang YH

American journal of clinical dermatology 2024; (25(3)):347-358 doi:10.1007/s40257-024-00849-0.

Successful Treatment of Refractory Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO) Syndrome and Paradoxical Psoriasis with Secukinumab: A Case Report.

Fan D, Li F, Liu Z, et al.

Clinical, cosmetic and investigational dermatology 2024; (17()):547-552 doi:10.2147/CCID.S454057.

Apremilast is a potentially useful treatment for severe palmoplantar pustulosis with extra-palmoplantar symptoms.

Fukushima-Nomura A, Takamiyagi S, Kakuta R, et al.

Skin health and disease 2024; (4(2)):e336 doi:10.1002/ski2.336.

A genome-wide meta-analysis of palmoplantar pustulosis implicates TH2 responses and cigarette smoking in disease pathogenesis.

Hernandez-Cordero A, Thomas L, Smail A, et al.

The Journal of allergy and clinical immunology 2024; (154(3)):657-665.e9 doi:10.1016/j.jaci.2024.05.015.

The challenging diagnosis of synovitis-acne-pustulosis-hyperostosis-osteitis (SAPHO) syndrome: A rare case report.

El Harras Y, Imrani K, Setti SE, et al.

SAGE open medical case reports 2024; (12()):2050313X241259395 doi:10.1177/2050313X241259395.

Exploratory Efficacy Evaluation of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: 32-Week Results from a Phase 2, Randomized, Placebo-Controlled Study.

Okubo Y, Terui T, Kobayashi S, et al.

Dermatology and therapy 2024; (14(7)):1863-1873 doi:10.1007/s13555-024-01195-z.

Efficacy and Safety of Brodalumab, an Anti-interleukin-17 Receptor A Monoclonal Antibody, for Palmoplantar Pustulosis: 16-Week Results of a Randomized Clinical Trial.

Okubo Y, Kobayashi S, Murakami M, et al.

American journal of clinical dermatology 2024; (25(5)):837-847 doi:10.1007/s40257-024-00876-x.

Janus kinase inhibitor tofacitinib successfully treated palmoplantar pustulosis after switching from secukinumab: A case report and review of the literature.

Fan Y, Yin R

International immunopharmacology 2024; (139()):112762 doi:10.1016/j.intimp.2024.112762.

Palmoplantar Psoriasis: Epidemiological and Clinical Features and Impact on Quality of Life.

Elinkichari D, Rabhi F, Jaber K, Dhaoui R

Dermatology practical & conceptual 2024; (14(3)) doi:10.5826/dpc.1403a191.

Palmoplantar Pustulosis has a Greater Disease Burden than Plaque Psoriasis: Real-World Evidence From the CorEvitas Psoriasis Registry.

Lebwohl MG, Medeiros RA, Mackey RH, et al.

Journal of psoriasis and psoriatic arthritis 2023; (8(2)):56-65 doi:10.1177/24755303221146990.

Insight into adenosine pathway in psoriasis: Elucidating its role and the potential therapeutical applications.

Giraulo C, De Palma G, Plaitano P, et al.

Life sciences 2024; (357()):123071 doi:10.1016/j.lfs.2024.123071.

A systematic review of recent randomized controlled trials for palmoplantar pustulosis.

Branyiczky MK, Towheed S, Torres T, Vender R

The Journal of dermatological treatment 2024; (35(1)):2414048 doi:10.1080/09546634.2024.2414048.

Successful treatment of refractory palmoplantar pustulosis by upadacitinib: report of 28 patients.

Du N, Yang J, Zhang Y, et al.

Frontiers in medicine 2024; (11()):1476793 doi:10.3389/fmed.2024.1476793.

Comments about the comparative bulk RNA sequencing between palmoplantar pustulosis and dyshidrotic palmoplantar eczema.

Yatsuzuka K, Muto J, Murakami M

F1000Research 2024; (13()):1494 doi:10.12688/f1000research.159565.1.

Determination of Risk Factors Influencing Psoriatic Arthritis Screening and Evaluation Questionnaire Scores in Palmoplantar Pustulosis: Post Hoc Analysis of EPPPIK Study.

Kim BS, Jo SJ, Kim DH, et al.

Dermatology and therapy 2025; (15(8)):2233-2246 doi:10.1007/s13555-025-01460-9.

An Analysis of IgG Antibody to Periodontopathic Bacteria in Serum of Palmoplantar Pustulosis Patients With Periodontitis.

Murai O, Chiba M, Suzuki K, et al.

The Journal of dermatology 2025; (52(12)):1811-1818 doi:10.1111/1346-8138.17939.

SAPHO Syndrome Misdiagnosed as Spinal Infection: A Case Series.

Yang X, Gu J, Zeng C, et al.

International medical case reports journal 2025; (18()):1329-1341 doi:10.2147/IMCRJ.S526910.

Extra-Palmoplantar Lesions of Palmoplantar Pustulosis: Underrecognized but Important Manifestation.

Yamamoto T

Indian journal of dermatology 2025; (70(6)):336-341 doi:10.4103/ijd.ijd_648_24.

The Relative Efficacy of Monotherapies for Palmoplantar Pustulosis and Palmoplantar Psoriasis: A Network Meta-Analysis Study of the Palmoplantar Spectrum.

Gupta AK, Bamimore MA, Wang T, et al.

Medicina (Kaunas, Lithuania) 2026; (62(2)) doi:10.3390/medicina62020400.

IL-36-Driven Inflammation in Generalized Pustular Psoriasis: Immunological Insights from Plaque Psoriasis and Implications for Targeted Therapy.

Andrzejczak K, Kucharczyk E, Sternak A, et al.

International journal of molecular sciences 2026; (27(10)) doi:10.3390/ijms27104441.

Treatment Guidance for Palmoplantar Pustulosis 2022.

, Terui T, Kobayashi S, et al.

The Journal of dermatology 2026; (53(7)):e510-e566 doi:10.1111/1346-8138.70246.

CT and MRI features of SAPHO syndrome: a report of 6 cases.

Xu K, Meng Y, Zuo T

BMC musculoskeletal disorders 2026; (27(1)).